Delivery of gene silencing agents for breast cancer therapy

Research output: Contribution to journalArticle

The discovery of RNA interference has opened the door for the development of a new class of cancer therapeutics. Small inhibitory RNA oligos are being designed to specifically suppress expression of proteins that are traditionally considered nondruggable, and microRNAs are being evaluated to exert broad control of gene expression for inhibition of tumor growth. Since most naked molecules are not optimized for in vivo applications, the gene silencing agents need to be packaged into delivery vehicles in order to reach the target tissues as their destinations. Thus, the selection of the right delivery vehicles serves as a crucial step in the development of cancer therapeutics. The current review summarizes the status of gene silencing agents in breast cancer and recent development of candidate cancer drugs in clinical trials. Nanotechnology-based delivery vectors for the formulation and packaging of gene silencing agents are also described.

Original languageEnglish
Article number205
JournalBreast Cancer Research
Volume15
Issue number3
DOIs
StatePublished - May 8 2013

PMID: 23659575

PMCID: PMC3706796

Altmetrics

Cite this

Standard

Delivery of gene silencing agents for breast cancer therapy. / Shen, Haifa; Mittal, Vivek; Ferrari, Mauro; Chang, Jenny C.

In: Breast Cancer Research, Vol. 15, No. 3, 205, 08.05.2013.

Research output: Contribution to journalArticle

Harvard

Shen, H, Mittal, V, Ferrari, M & Chang, JC 2013, 'Delivery of gene silencing agents for breast cancer therapy' Breast Cancer Research, vol. 15, no. 3, 205. https://doi.org/10.1186/bcr3413

APA

Shen, H., Mittal, V., Ferrari, M., & Chang, J. C. (2013). Delivery of gene silencing agents for breast cancer therapy. Breast Cancer Research, 15(3), [205]. https://doi.org/10.1186/bcr3413

Vancouver

Shen H, Mittal V, Ferrari M, Chang JC. Delivery of gene silencing agents for breast cancer therapy. Breast Cancer Research. 2013 May 8;15(3). 205. https://doi.org/10.1186/bcr3413

Author

Shen, Haifa ; Mittal, Vivek ; Ferrari, Mauro ; Chang, Jenny C. / Delivery of gene silencing agents for breast cancer therapy. In: Breast Cancer Research. 2013 ; Vol. 15, No. 3.

BibTeX

@article{15d8a54b18ef470a899f19b652891856,
title = "Delivery of gene silencing agents for breast cancer therapy",
abstract = "The discovery of RNA interference has opened the door for the development of a new class of cancer therapeutics. Small inhibitory RNA oligos are being designed to specifically suppress expression of proteins that are traditionally considered nondruggable, and microRNAs are being evaluated to exert broad control of gene expression for inhibition of tumor growth. Since most naked molecules are not optimized for in vivo applications, the gene silencing agents need to be packaged into delivery vehicles in order to reach the target tissues as their destinations. Thus, the selection of the right delivery vehicles serves as a crucial step in the development of cancer therapeutics. The current review summarizes the status of gene silencing agents in breast cancer and recent development of candidate cancer drugs in clinical trials. Nanotechnology-based delivery vectors for the formulation and packaging of gene silencing agents are also described.",
author = "Haifa Shen and Vivek Mittal and Mauro Ferrari and Chang, {Jenny C.}",
year = "2013",
month = "5",
day = "8",
doi = "10.1186/bcr3413",
language = "English",
volume = "15",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "3",

}

RIS

TY - JOUR

T1 - Delivery of gene silencing agents for breast cancer therapy

AU - Shen, Haifa

AU - Mittal, Vivek

AU - Ferrari, Mauro

AU - Chang, Jenny C.

PY - 2013/5/8

Y1 - 2013/5/8

N2 - The discovery of RNA interference has opened the door for the development of a new class of cancer therapeutics. Small inhibitory RNA oligos are being designed to specifically suppress expression of proteins that are traditionally considered nondruggable, and microRNAs are being evaluated to exert broad control of gene expression for inhibition of tumor growth. Since most naked molecules are not optimized for in vivo applications, the gene silencing agents need to be packaged into delivery vehicles in order to reach the target tissues as their destinations. Thus, the selection of the right delivery vehicles serves as a crucial step in the development of cancer therapeutics. The current review summarizes the status of gene silencing agents in breast cancer and recent development of candidate cancer drugs in clinical trials. Nanotechnology-based delivery vectors for the formulation and packaging of gene silencing agents are also described.

AB - The discovery of RNA interference has opened the door for the development of a new class of cancer therapeutics. Small inhibitory RNA oligos are being designed to specifically suppress expression of proteins that are traditionally considered nondruggable, and microRNAs are being evaluated to exert broad control of gene expression for inhibition of tumor growth. Since most naked molecules are not optimized for in vivo applications, the gene silencing agents need to be packaged into delivery vehicles in order to reach the target tissues as their destinations. Thus, the selection of the right delivery vehicles serves as a crucial step in the development of cancer therapeutics. The current review summarizes the status of gene silencing agents in breast cancer and recent development of candidate cancer drugs in clinical trials. Nanotechnology-based delivery vectors for the formulation and packaging of gene silencing agents are also described.

UR - http://www.scopus.com/inward/record.url?scp=84877650524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877650524&partnerID=8YFLogxK

U2 - 10.1186/bcr3413

DO - 10.1186/bcr3413

M3 - Article

VL - 15

JO - Breast Cancer Research

T2 - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 3

M1 - 205

ER -

ID: 3290443